Depression impacts approximately 265 million people in the world. According to WHO, it is one of the primary causes of disability. There are currently two known compounds, TD-0148A, and TD-010, for treating neurological disorders. Thanks to BetterLife Pharma Inc. (OTCMKTS: BETRF), a biotech focused on developing and commercializing the two compounds. The good news is that TD-0148Ais unregulated and therefore can be self-administered hence eliminating regulatory hurdles.
Betterlife has expanded its focus and is seeking strategic alternatives to fight the COVID-19 disease. This is the reason why it has initiated Vitro studies of its recombinant human interferon AP-003 against the Delta variant of SARS-CoV-2. The study is at Dr. Stephen Barr’s Laboratory, a state-of-the-art ImPaKT Facility at Western University.
The Effects Of Interferon Against Different Variants
COVID-19 is still a huge threat to the global population. Additionally, the emerging variants are also a challenge in the development of therapeutics. According to the CEO of BetterLife, Ahmad Doroudian, scientists hypothesize the broad mechanism of action of interferon to make it more effective against different variants.
He outlined, “The global vaccine roll-out is making headway; however, there are still several reasons why there is a need for an effective, easy to administer, non-invasive treatment, such as AP-003….” and being a Type I interferon, it is a broad-acting anti-viral agent. Its presence makes the world a step closer to reducing the overall severity of the disease, including hospitalization and death rate.
A New Agreement to Carry out TD-0148A Pre – Clinical Receptor Binding Studies
According to BetterLife, TD-0148A is likely to mimic the projected therapeutic potential of LSD without the undesirable side effects. As a result, the company has entered into a research pact with the Medical College of Wisconsin to carry out TD-0148A preclinical receptor binding studies. Dr. John McCorvy’s Laboratory and his team will integrate with BetterLife to understand how psychedelics or related compounds interact with the serotonin systems. They will also seek a better understanding of the neurological receptor pharmacology of TD-0148A’s novel mechanism of action.
Tauriga Sciences, Inc. (OTCMKTS: TAUG) Sets up a Clinical Trial to Determine the effects of Cannabidiol on Pregnant Women with a Hyperemesis Gravidarum Diagnosis.
Post Views: 2 Nausea and vomiting are very common in early pregnancy, and the victims have to ingest multiple medications....
BetterLife Pharma Inc. (OTCMKTS: BETRF) Announce Initiation Of In Vitro Studies of AP-003 Against The Delta Variant of SARS-CoV-2
Post Views: 16 Depression impacts approximately 265 million people in the world. According to WHO, it is one of the...
Ayr Wellness Inc. (OTCMKTS: AYRWF) Signs a Binding Letter of Intent to Acquire PA Natural Medicine, LLC
Post Views: 16 Curiosity about cannabis is building by the day as more expert cultivators, manufactures, budtenders, and patient consultants...
Schwazze (OTCMKTS: SHWZ) Spends $6.7 Million to Acquire the Assets of Brow 2, LLC, Located in Denver, Colorado
Post Views: 19 Innovative thinking is what will keep the next era of the cannabis industry alive. This is according...
Valens Company Inc (OTCMKTS: VLNCF) Acquires Leading, Premium Craft Licensed producer, Citizen Stash Cannabis Corp
Post Views: 89 Valens Company Inc (OTCMKTS: VLNCF), a leading manufacturer of cannabis products, announced that it entered into an...
Harvest One Cannabis Inc’s (OTCMKTS: HRVOF) Dream Water Brand Launches its Sleep Gummies into the American Market
Post Views: 95 Harvest One Cannabis Inc (OTCMKTS: HRVOF) reported that its Dream Water launched sleep gummies for a new...